| Prev Close | 77.73 |
| Open | 77.61 |
| Day Low/High | 77.03 / 79.18 |
| 52 Wk Low/High | 62.88 / 100.13 |
| Volume | 2.05M |
| Avg Volume | 1.38M |
BioMarin Pharmaceutical Inc. (BMRN)
77.34
0.39
0.50
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 179.62M |
| Market Cap | 13.50B |
| EPS | -0.40 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
3 Biotech Plays That Would Work as Covered Calls
The SPDR S&P Biotech ETF, Alexion Pharmaceuticals and BioMarin Pharmaceuticals set up nicely for this options strategy.
Otezla Price Under Microscope -- but Look Closely and It Checks Out
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
A Handful of Small Biotechs That Make for Merger Chatter
The names include a veterinary drug concern plus companies with successful drugs on the market.
2 Stocks You Definitely Should Consider Shorting This Week
These 'Bearish Bets' are showing both technical and quantitative deterioration.
Here's How I'm Playing an Increasingly Volatile Market With These 2 Biotechs
I am incrementally using buy-write option orders to add some shares to core holdings.
10 Speculative Stock Plays in the Biotech Sector
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019
It has been a better year for the Russell 2000 and the small-caps it represents.
Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop
It is all about perception, and here are strong names to pick up on market weakness.
Charts: BioMarin Pharmaceutical Could Rise 30% From Here
I have not seen a bullish breakout from a large base pattern in a while.
BioMarin Paces a Very Strong Biotech Group
Here's how BMRN's chart looks after its blistering gains.
These Biotechs Are Movers Today
The market is down across the board as one might expect given escalating trade tensions today. However, losses are slight in this context in the first hour of trading. Given the option expiration date, volatility could pick up later in the day. Some...
Probing the Long Side of BioMarin
Latest surge boosts chances of breakout in shares of BioMarin.
BioMarin Pharmaceutical Is Doing Better but Patience Is Needed
The upswing is welcomed but it still is not an important breakout of the two-year sideways pattern.
Here's My Take on Biotech Stocks
I think M&A activity will pick up markedly going forward across the industry.
Why I Stay Very Focused on My Individual Stocks
I do not need to come up with any grand arguments for a bullish or bearish bias. It happens by default.
Allergan, BioMarin Hold Promise for 2018
The stocks of these two larger-cap biopharma names seem poised to stage comebacks next year.
10 Biotech Stocks Investors Should Put on Their Shopping List for 2018
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
10 Biotech Stocks to Watch in 2018
There are a variety of players that should be active in the M&A space next year.
Who Benefits From Tax Reform?
Technology and biotech companies seem to be among the big winners.
Trump's FDA: A Friendlier Biotech Sheriff
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
3 Fearless Predictions for the Second Half
The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.
3 Fearless Predictions for the Second Half
The FAANG stocks will underperform, banks will do well and biotech merger action will pick up.
Cramer: There Are Powerful Themes in Several Bull Markets
It's a wonder to me how split this market really is.
I'm Big on Housing Entering Quarter No. 2
Home builders make up the second-largest allocation in my portfolio, behind biotech.
Biotech Should Witness M&A's Return in 2017
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
BioMarin Surging Beneath the Surface
The pharmaceutical stock is about to go from sideways to up.
